Shenzhen - Delayed Quote CNY

Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ)

70.15 +1.75 (+2.56%)
At close: April 26 at 3:04 PM GMT+8
Key Events
Loading Chart for 300832.SZ
DELL
  • Previous Close 68.40
  • Open 68.43
  • Bid 70.15 x --
  • Ask 70.16 x --
  • Day's Range 68.30 - 70.51
  • 52 Week Range 49.86 - 83.50
  • Volume 4,921,527
  • Avg. Volume 3,514,723
  • Market Cap (intraday) 55.118B
  • Beta (5Y Monthly) -0.61
  • PE Ratio (TTM) 33.40
  • EPS (TTM) 2.10
  • Earnings Date --
  • Forward Dividend & Yield 0.70 (1.00%)
  • Ex-Dividend Date Jun 8, 2023
  • 1y Target Est 80.92

Shenzhen New Industries Biomedical Engineering Co., Ltd., a bio-medical company, engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in the People's Republic of China and internationally. It offers immunoassay, biochemistry/electrolyte, molecular diagnostics, point of care testing, lab automation, and integrated system, products. The company was founded in 1995 and is headquartered in Shenzhen, the People's Republic of China.

www.snibe.com

2,627

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: 300832.SZ

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

300832.SZ
10.29%
SSE Composite Index
3.82%

1-Year Return

300832.SZ
28.88%
SSE Composite Index
5.40%

3-Year Return

300832.SZ
2.16%
SSE Composite Index
11.10%

5-Year Return

300832.SZ
--
SSE Composite Index
6.82%

Compare To: 300832.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300832.SZ

Valuation Measures

Annual
As of 4/28/2024
  • Market Cap

    55.12B

  • Enterprise Value

    51.99B

  • Trailing P/E

    33.34

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.03

  • Price/Book (mrq)

    7.31

  • Enterprise Value/Revenue

    13.23

  • Enterprise Value/EBITDA

    25.39

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    42.32%

  • Return on Assets (ttm)

    14.25%

  • Return on Equity (ttm)

    23.44%

  • Revenue (ttm)

    4.08B

  • Net Income Avi to Common (ttm)

    1.72B

  • Diluted EPS (ttm)

    2.10

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.3B

  • Total Debt/Equity (mrq)

    0.06%

  • Levered Free Cash Flow (ttm)

    999.42M

Research Analysis: 300832.SZ

Analyst Price Targets

64.00 Low
80.92 Average
70.15 Current
98.15 High
 

Fair Value

 

Company Insights: 300832.SZ

People Also Watch